{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:21:58Z","timestamp":1784305318391,"version":"3.55.0"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Osteoporosis therapies have become increasingly relevant to cardiovascular medicine because the bone\u2013vascular interface links skeletal remodeling to vascular calcification biology. This narrative review examines whether anti-osteoporosis therapies truly modify coronary biology or risk, or whether the current literature more often reflects heterogeneous vascular end points, indirect coronary inference, and incomplete translation from mechanistic plausibility to clinical outcomes. We summarize the biologic pathways connecting bone remodeling to vascular calcification, including osteogenic transdifferentiation of vascular smooth muscle cells, matrix vesicle-mediated mineralization, the OPG\/RANKL axis, and Wnt\u2013sclerostin signaling. We then reassess current evidence for antiresorptive and osteoanabolic therapies while distinguishing coronary-specific data from broader vascular, renal-mineral, pharmacovigilance, and genetic evidence. Bisphosphonates and denosumab remain biologically relevant to vascular calcification, but based on currently available evidence, current studies do not support a reproducible or clinically decisive effect on coronary-specific outcomes. By contrast, romosozumab has sharpened the debate because it combines robust anti-fracture efficacy with unresolved cardiovascular safety questions linked to sclerostin inhibition, whose mechanistic, genetic, and clinical signals are not fully concordant. We further discuss why the literature remains conflicted, emphasizing end point heterogeneity, differences between calcification burden and plaque vulnerability, population-specific mineral stress, and the limitations of fracture trials for coronary inference. Overall, current evidence does not support a uniform cardiovascular class effect of osteoporosis therapies; instead, vascular consequences appear drug-specific, context-dependent, and highly sensitive to phenotype, baseline risk, and time horizon.<\/jats:p>","DOI":"10.3389\/fendo.2026.1839111","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T04:35:05Z","timestamp":1777437305000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Osteoporosis therapies and coronary risk: insights from vascular calcification biology and sclerostin signaling"],"prefix":"10.3389","volume":"17","author":[{"given":"Shuwei","family":"Weng","sequence":"first","affiliation":[{"name":"Cardiovascular Department, The First Affiliated Hospital, Fujian Medical University, Key Laboratory of Metabolic Heart Disease in Fujian Province, Clinical Research Centre of Metabolic Cardiovascular Disease in Fujian Province","place":["Fuzhou, China"]},{"name":"Cardiovascular Department, National Regional Medical Center, Binhai Branch of the First Affiliated Hospital, Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Ding","sequence":"additional","affiliation":[{"name":"Cardiovascular Department, The First Affiliated Hospital, Fujian Medical University, Key Laboratory of Metabolic Heart Disease in Fujian Province, Clinical Research Centre of Metabolic Cardiovascular Disease in Fujian Province","place":["Fuzhou, China"]},{"name":"Cardiovascular Department, National Regional Medical Center, Binhai Branch of the First Affiliated Hospital, Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Shi","sequence":"additional","affiliation":[{"name":"Cardiovascular Department, The First Affiliated Hospital, Fujian Medical University, Key Laboratory of Metabolic Heart Disease in Fujian Province, Clinical Research Centre of Metabolic Cardiovascular Disease in Fujian Province","place":["Fuzhou, China"]},{"name":"Cardiovascular Department, National Regional Medical Center, Binhai Branch of the First Affiliated Hospital, Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Cardiovascular Department, The First Affiliated Hospital, Fujian Medical University, Key Laboratory of Metabolic Heart Disease in Fujian Province, Clinical Research Centre of Metabolic Cardiovascular Disease in Fujian Province","place":["Fuzhou, China"]},{"name":"Cardiovascular Department, National Regional Medical Center, Binhai Branch of the First Affiliated Hospital, Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxiang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Cardiovascular Department, The First Affiliated Hospital, Fujian Medical University, Key Laboratory of Metabolic Heart Disease in Fujian Province, Clinical Research Centre of Metabolic Cardiovascular Disease in Fujian Province","place":["Fuzhou, China"]},{"name":"Cardiovascular Department, National Regional Medical Center, Binhai Branch of the First Affiliated Hospital, Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Zhu","sequence":"additional","affiliation":[{"name":"Cardiovascular Department, The First Affiliated Hospital, Fujian Medical University, Key Laboratory of Metabolic Heart Disease in Fujian Province, Clinical Research Centre of Metabolic Cardiovascular Disease in Fujian Province","place":["Fuzhou, China"]},{"name":"Cardiovascular Department, National Regional Medical Center, Binhai Branch of the First Affiliated Hospital, Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Peng","sequence":"additional","affiliation":[{"name":"Cardiovascular Department, The First Affiliated Hospital, Fujian Medical University, Key Laboratory of Metabolic Heart Disease in Fujian Province, Clinical Research Centre of Metabolic Cardiovascular Disease in Fujian Province","place":["Fuzhou, China"]},{"name":"Cardiovascular Department, National Regional Medical Center, Binhai Branch of the First Affiliated Hospital, Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dajun","family":"Chai","sequence":"additional","affiliation":[{"name":"Cardiovascular Department, The First Affiliated Hospital, Fujian Medical University, Key Laboratory of Metabolic Heart Disease in Fujian Province, Clinical Research Centre of Metabolic Cardiovascular Disease in Fujian Province","place":["Fuzhou, China"]},{"name":"Cardiovascular Department, National Regional Medical Center, Binhai Branch of the First Affiliated Hospital, Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-022-08088-4","article-title":"Osteoporosis and cardiovascular disease: a review","volume":"50","author":"Azeez","year":"2023","journal-title":"Mol Biol Rep"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcha.2021.100891","article-title":"Low bone mineral density and coronary artery disease: a systematic review and meta-analysis","volume":"37","author":"Khandkar","year":"2021","journal-title":"Int J Cardiol Heart Vasc"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1177\/20406223221086998","article-title":"Associations between bone mineral density and coronary artery calcification: a systematic review and meta-analysis","volume":"13","author":"Zhang","year":"2022","journal-title":"Ther Adv Chronic Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-139X.2007.00255.x","article-title":"The vascular biology of calcification","volume":"20","author":"Shroff","year":"2007","journal-title":"Semin Dial"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcm.2014.10.021","article-title":"Vascular calcification: mechanisms of vascular smooth muscle cell calcification","volume":"25","author":"Leopold","year":"2015","journal-title":"Trends Cardiovasc Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2022-321711","article-title":"Coronary artery calcium: from risk prediction to treatment allocation and clinical trials","volume":"109","author":"Whelton","year":"2023","journal-title":"Heart"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000031524.49139.29","article-title":"Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease","volume":"106","author":"Jono","year":"2002","journal-title":"Circulation"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.03.013","article-title":"Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity","volume":"55","author":"Venuraju","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.708470","article-title":"Wnt signaling in vascular calcification","volume":"8","author":"Bundy","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2016.06.039","article-title":"Bisphosphonates for cardiovascular risk reduction: a systematic review and meta-analysis","volume":"252","author":"Kranenburg","year":"2016","journal-title":"Atherosclerosis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-084516","article-title":"Do bisphosphonates and RANKL inhibitors alter the progression of coronary artery calcification? A systematic review","volume":"14","author":"Saunders","year":"2024","journal-title":"BMJ Open"},{"key":"B12","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/jbmr.4157","article-title":"Cardiovascular safety of denosumab across multiple indications: a systematic review and meta-analysis of randomized trials","volume":"36","author":"Seeto","year":"2021","journal-title":"J Bone Miner Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jot.2024.07.011","article-title":"Treatment effects, adverse outcomes and cardiovascular safety of romosozumab - existing worldwide data: a systematic review and meta-analysis","volume":"48","author":"Wong","year":"2024","journal-title":"J Orthop Translat"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.639740","article-title":"The cell origin and role of osteoclastogenesis and osteoblastogenesis in vascular calcification","volume":"8","author":"Jiang","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/bioengineering7030088","article-title":"Mechanisms of the osteogenic switch of smooth muscle cells in vascular calcification: WNT signaling, BMPs, mechanotransduction, and EndMT","volume":"7","author":"Tyson","year":"2020","journal-title":"Bioengineering (Basel)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.07.019","article-title":"Matrix vesicles induce calcification of recipient vascular smooth muscle cells through multiple signaling pathways","volume":"93","author":"Chen","year":"2018","journal-title":"Kidney Int"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejvs.2017.12.009","article-title":"Mechanisms of arterial calcification: the role of matrix vesicles","volume":"55","author":"Zazzeroni","year":"2018","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.825622","article-title":"Matrix vesicles as a therapeutic target for vascular calcification","volume":"10","author":"Li","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000149165.99974.12","article-title":"Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin","volume":"95","author":"Collin-Osdoby","year":"2004","journal-title":"Circ Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/nu10040415","article-title":"Is matrix Gla protein associated with vascular calcification? A systematic review","volume":"10","author":"Barrett","year":"2018","journal-title":"Nutrients"},{"key":"B21","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12872-016-0362-8","article-title":"Wnt signaling contributes to vascular calcification by induction of matrix metalloproteinases","volume":"16","author":"Freise","year":"2016","journal-title":"BMC Cardiovasc Disord"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2022.2114370","article-title":"Sclerostin is involved in osteogenic transdifferentiation of vascular smooth muscle cells in chronic kidney disease-associated vascular calcification with non-canonical Wnt signaling","volume":"44","author":"Xiao","year":"2022","journal-title":"Ren Fail"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2008.218","article-title":"Does Fgf23-klotho activity influence vascular and soft tissue calcification through regulating mineral ion metabolism","volume":"74","author":"Memon","year":"2008","journal-title":"Kidney Int"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2174\/1570161115666170310092202","article-title":"Klotho-FGF23, cardiovascular disease, and vascular calcification: black or white","volume":"16","author":"Cianciolo","year":"2018","journal-title":"Curr Vasc Pharmacol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.athplu.2026.01.001","article-title":"Bisphosphonates use is associated with increased coronary artery calcification in the general population: the Rotterdam study","volume":"63","author":"Shahraki","year":"2026","journal-title":"Atheroscler Plus"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S138002","article-title":"Bisphosphonates, atherosclerosis and vascular calcification: update and systematic review of clinical studies","volume":"12","author":"Caffarelli","year":"2017","journal-title":"Clin Interv Aging"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-020-05430-z","article-title":"Once-yearly zoledronic acid and change in abdominal aortic calcification over 3 years in postmenopausal women with osteoporosis: results from the HORIZON pivotal fracture trial","volume":"31","author":"Cai","year":"2020","journal-title":"Osteoporos Int"},{"key":"B28","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12872-025-04526-w","article-title":"Nitrogen-containing bisphosphonate for vascular calcification: animal experiments, systematic review and meta-analysis","volume":"25","author":"Xu","year":"2025","journal-title":"BMC Cardiovasc Disord"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2043","article-title":"RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk","volume":"29","author":"Samelson","year":"2014","journal-title":"J Bone Miner Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000039642","article-title":"Effect of denosumab, an anti-osteoporosis drug, on vascular calcification: a meta-analysis","volume":"103","author":"Wang","year":"2024","journal-title":"Medicine (Baltimore)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2020.12.002","article-title":"Denosumab recovers aortic arch calcification during long-term hemodialysis","volume":"6","author":"Suzuki","year":"2020","journal-title":"Kidney Int Rep"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/jbmrpl\/ziae146","article-title":"Cardiovascular outcomes of romosozumab treatment-real-world data analysis","volume":"9","author":"Tsur","year":"2024","journal-title":"JBMR Plus"},{"key":"B35","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1007\/s00774-024-01531-5","article-title":"Efficacy and safety of romosozumab: a meta-analysis of placebo-controlled trials","volume":"42","author":"Kobayashi","year":"2024","journal-title":"J Bone Miner Metab"},{"key":"B36","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s40264-024-01475-9","article-title":"Cardiovascular safety of romosozumab compared to commonly used anti-osteoporosis medications in postmenopausal osteoporosis: a systematic review and network meta-analysis of randomized controlled trials","volume":"48","author":"Cheng","year":"2025","journal-title":"Drug Saf"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae173","article-title":"Cardiovascular safety of romosozumab vs PTH analogues for osteoporosis treatment: a propensity-score-matched cohort study","volume":"110","author":"Stokar","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-024-07255-6","article-title":"Comparative effectiveness and cardiovascular safety of romosozumab versus teriparatide in patients with osteoporosis: a population-based cohort study","volume":"35","author":"Masuda","year":"2024","journal-title":"Osteoporos Int"},{"key":"B39","doi-asserted-by":"publisher","first-page":"9832","DOI":"10.1038\/s41467-024-53623-5","article-title":"Effect of genetically predicted sclerostin on cardiovascular biomarkers, risk factors, and disease outcomes","volume":"15","author":"Alcalde-Herraiz","year":"2024","journal-title":"Nat Commun"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10081660","article-title":"Cardiovascular safety profile of romosozumab: a pharmacovigilance analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS)","volume":"10","author":"Vestergaard Kvist","year":"2021","journal-title":"J Clin Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2020.104697","article-title":"Nonclinical cardiovascular safety evaluation of romosozumab, an inhibitor of sclerostin for the treatment of osteoporosis in postmenopausal women at high risk of fracture","volume":"115","author":"Turk","year":"2020","journal-title":"Regul Toxicol Pharmacol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa450","article-title":"Cardiovascular safety of abaloparatide in postmenopausal women with osteoporosis: analysis from the ACTIVE phase 3 trial","volume":"105","author":"Cosman","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.06.038","article-title":"Coronary artery calcium progression: an important clinical measurement? A review of published reports","volume":"56","author":"McEvoy","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.282535","article-title":"Calcium density of coronary artery plaque and risk of incident cardiovascular events","volume":"311","author":"Criqui","year":"2014","journal-title":"JAMA"},{"key":"B45","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.jcmg.2024.07.024","article-title":"Coronary artery calcium density and risk of cardiovascular events: a systematic review and meta-analysis","volume":"18","author":"Yong","year":"2025","journal-title":"JACC Cardiovasc Imaging"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2013.03.010","article-title":"Coronary calcification identifies the vulnerable patient rather than the vulnerable plaque","volume":"229","author":"Mauriello","year":"2013","journal-title":"Atherosclerosis"},{"key":"B47","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.atherosclerosis.2020.05.017","article-title":"Calcium deposition within coronary atherosclerotic lesion: implications for plaque stability","volume":"306","author":"Jinnouchi","year":"2020","journal-title":"Atherosclerosis"},{"key":"B48","doi-asserted-by":"publisher","first-page":"34","DOI":"10.4103\/tcmj.tcmj_36_20","article-title":"Vascular calcification of chronic kidney disease: a brief review","volume":"33","author":"Hsu","year":"2020","journal-title":"Tzu Chi Med J"},{"key":"B49","article-title":"Vascular calcification in chronic kidney disease: mechanisms and clinical implications","volume":"5","author":"Ossareh","year":"2011","journal-title":"Iran J Kidney Dis"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1080\/08039488.2023.2210108","article-title":"Beware of confounding by indication in pharmacoepidemiological studies","volume":"77","author":"\u00d8stergaard","year":"2023","journal-title":"Nord J Psychiatry"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa048","article-title":"Pharmacological management of osteoporosis in postmenopausal women: An endocrine society guideline update","volume":"105","author":"Shoback","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2022.2152320","article-title":"Romosozumab for the treatment of postmenopausal women at high risk of fracture","volume":"23","author":"Geusens","year":"2023","journal-title":"Expert Opin Biol Ther"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-025-01590-2","article-title":"Sequential and combination therapy with romosozumab","volume":"43","author":"Kobayakawa","year":"2025","journal-title":"J Bone Miner Metab"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2024.117305","article-title":"Cardiovascular risk assessment for osteoporosis patients considering romosozumab","volume":"190","author":"Macrae","year":"2025","journal-title":"Bone"},{"key":"B55","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11914-020-00652-w","article-title":"Romosozumab: a review of efficacy, safety, and cardiovascular risk","volume":"19","author":"Fixen","year":"2021","journal-title":"Curr Osteoporos Rep"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4563","article-title":"Efficacy and safety of romosozumab among postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease","volume":"37","author":"Miller","year":"2022","journal-title":"J Bone Miner Res"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2024.118618","article-title":"Coronary artery calcium density progression: Should we measure it","volume":"398","author":"Razavi","year":"2024","journal-title":"Atherosclerosis"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.120.313785","article-title":"18F-sodium fluoride (18F-NaF) for imaging microcalcification activity in the cardiovascular system","volume":"40","author":"Tzolos","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-019-04667-z","article-title":"Whole-vessel coronary 18F-sodium fluoride PET for assessment of the global coronary microcalcification burden","volume":"47","author":"Kwiecinski","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12247615","article-title":"CT coronary angiography: Technical approach and atherosclerotic plaque characterization","volume":"12","author":"Dell'Aversana","year":"2023","journal-title":"J Clin Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.0000000000000152","article-title":"Target trial emulation to improve causal inference from observational data: What, why, and how","volume":"34","author":"Fu","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13643-023-02442-8","article-title":"Mendelian randomization studies on coronary artery disease: a systematic review and meta-analysis","volume":"13","author":"Silva","year":"2024","journal-title":"Syst Rev"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1839111\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T04:35:16Z","timestamp":1777437316000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1839111\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":62,"alternative-id":["10.3389\/fendo.2026.1839111"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1839111","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"article-number":"1839111"}}